Company intelligence / Profile preview
Tacitus Therapeutics
New York, NY, United Statestacitustherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tacitus Therapeutics has developed a proprietary technology to expand, differentiate, and engineer hematopoietic stem cells. Their lead candidate HSC100 entered Phase I trials targeting blood cancers. The company aims to overcome limitations of traditional allogeneic transplantation such as graft-versus-host disease and delayed platelet engraftment. Preclinical work addresses clotting disorders like thrombocytopenia[1][2][3][4]. No published clinical results yet.
- Therapeutic areas
- Hematology
- Modalities
- Engineered hematopoietic stem cells (HSCs)Other engineered immune cells
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Mount Sinai Health System—exclusive technology license & collaboration partner[1][3][4].
Beyond the preview
Go deeper on Tacitus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tacitus Therapeutics.